Author:
Desar I.M.E.,Burger D.M.,Van Hoesel Q.G.C.M.,Beijnen J.H.,Van Herpen C.M.L.,Van der Graaf W.T.A.
Reference4 articles.
1. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer;Faivre;J Clin Oncol,2006
2. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period;Britten;Cancer Chemother Pharmacol,2008
3. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship;Mendel;Clin Cancer Res,2003
4. Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): a population pharmacokinetic/pharmacodynamic (PKPD) approach;Houk;J Clin Oncol,2007
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献